On Tuesday, Shares of Southwest Airlines Co (NYSE:LUV), gained 0.19% to $46.46.
Southwest Airlines is bringing not one, but two daily flights from Baltimore/Washington to Minneapolis/St. Paul. The new, twice-daily, nonstop service starts on April 12, 2016, with fares as low as $79 one-way.
Purchase Nov.9 through Nov. 19, 2015, 11:59 p.m. in the respective time zone of the originating city. Travel April 12 through May 26, 2016. Travel is not valid on Fridays and Sundays. Fares are valid on nonstop, domestic service only. Displayed prices comprise all U.S. government taxes and fees. Points bookings do not comprise September 11th Security Fee of $5.60 per one-way flight. Seats and days are limited. See additional and complete fare rules below.
“At Southwest the bare facts are simply that two checked bags, airport check-in, carry-on bags, ticket changes, non-alcoholic drinks, and of course snacks are NOT so-called optional services, “said Andrew Watterson, Southwest Airlines Senior Vice President of Network and Revenue Administration. “We believe that it’s not in the holiday spirit to charge bag fees for the first two checked bags, much less even higher bag fees, during the holiday season.”
Southwest Airlines Co. operates passenger airlines that provide planned air transportation services in the United States and near-international markets. As of December 31, 2014, it operated 665 Boeing 737 aircraft; and had 12 Boeing 717 aircraft. The company served 93 destinations in 40 states, the District of Columbia, and the Commonwealth of Puerto Rico, in addition to 5 near-international countries, counting Mexico, Jamaica, The Bahamas, Aruba, and the Dominican Republic.
Shares of Ericsson (ADR) (NASDAQ:ERIC), declined -6.31% to $9.36, during its last trading session.
Ericsson, will hold its Capital Markets Day in Stockholm. The company will give an update on the progress of its Networked Society strategy, focusing on market development, growth agenda, and profitability.
Hans Vestberg, President and CEO, says: “We are ongoing our journey to transform Ericsson into a leading ICT player, building on our leadership in our core business and extending into targeted growth areas.”
The partnership with Cisco declared on November 9, targeting USD 1 billion or more in additional sales by 2018, will be talked about by Hans Vest berg and John Chambers, Executive Chairman, Cisco.
Hans Vestberg continues: “The partnership with Cisco is a key step forward in our company transformation and enables us to create unique value for our customers. Together, we will build on our longstanding technology and services leadership to define the networks of the future and accelerate realization of the Networked Society.”
Ericsson provides communications technology and services worldwide. The company’s Networks segment delivers products and solutions for mobile access, Internet protocol (IP) and transmission networks, core networks, and cloud.
Finally, Shares of Depomed Inc (NASDAQ:DEPO), ended its last trade with 5.47% gain, and closed at $21.21.
Depomed, stated financial results and highlighted operational achievements for the quarter ended September 30, 2015.
“Depomed is now one of the top U.S. companies in pain and neurology. In the third quarter, the company achieved historic highs in product sales, driven by noteworthy growth in both prescriptions and market share,” said Jim Schoeneck, President and CEO of Depomed. “Our new flagship franchise NUCYNTA, which we began promoting in June, led the way with revenue growing 15% over the preceding quarter. In October, we hit all-time weekly prescription highs for NUCYNTA ER, Gralise and Cambia, reflecting the outstanding work of our sales force across the entire product line. Depomed raised cash by $107 million in the six months since the close of the NUCYNTA transaction, providing noteworthy financial flexibility to pay down debt and to pursue additional acquisitions, as we continue to create substantial value for shareholders. Based on our financial performance, we are raising 2015 product sales guidance to $336 to $348 million, which is more than triple our 2014 product sales. In addition, we are raising our 2015 non-GAAP adjusted EBITDA to $108 to $116 million, up from our preceding guidance of $95 to 110 million and our non-GAAP adjusted earnings to $58 to $66 million, up from our preceding guidance of $40 to $50 million. And our 2015 numbers comprise just three quarters of NUCYNTA revenue. We believe that we are only at the very starting of a story with substantial revenue and earnings growth ahead for years to come.”
Depomed, Inc., a specialty pharmaceutical company, develops products for pain and other central nervous system conditions in the United States. It offers Gralise (gabapentin), an once-daily product for the administration of postherpetic neuralgia; CAMBIA (diclofenac potassium for oral solution), a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks in adults; Zipsor (diclofenac potassium) liquid filled capsule, a non-steroidal anti-inflammatory drug for the treatment of mild to moderate acute pain in adults; and Lazanda (fentanyl) nasal spray, an intranasal fentanyl drug used to manage breakthrough pain in adults.